Detail (Long)
If 5% to <20% (intermediate) ASCVD risk:<br>
• Initiate at least moderate-intensity (30%-49% LDL-C–lowering) statin tx [AI]:<br>
◦ <a href=https://online.epocrates.com/e/deeplink/drugs/10a5744/pitavastatin><u>pitavastatin</u></a> 4 mg qd [AI]<br>
◦ <a href=https://online.epocrates.com/e/deeplink/drugs/10a879/atorvastatin><u>atorvastatin</u></a> 20 mg qd [AII]<br>
◦ <a href=https://online.epocrates.com/e/deeplink/drugs/10a3476/rosuvastatin><u>rosuvastatin</u></a> 10 mg qd [AII]<br>
• Atorvastatin and rosuvastatin interact w/ ritonavir- and cobicistat-boosted ARVs.<br>
• If pregnant: Defer statin tx initiation until after pregnancy in pts at low to intermediate ASCVD risk. If on statin tx, discontinue. Breastfeeding is <i>not</i> recommended while on statin tx.
• Initiate at least moderate-intensity (30%-49% LDL-C–lowering) statin tx [AI]:<br>
◦ <a href=https://online.epocrates.com/e/deeplink/drugs/10a5744/pitavastatin><u>pitavastatin</u></a> 4 mg qd [AI]<br>
◦ <a href=https://online.epocrates.com/e/deeplink/drugs/10a879/atorvastatin><u>atorvastatin</u></a> 20 mg qd [AII]<br>
◦ <a href=https://online.epocrates.com/e/deeplink/drugs/10a3476/rosuvastatin><u>rosuvastatin</u></a> 10 mg qd [AII]<br>
• Atorvastatin and rosuvastatin interact w/ ritonavir- and cobicistat-boosted ARVs.<br>
• If pregnant: Defer statin tx initiation until after pregnancy in pts at low to intermediate ASCVD risk. If on statin tx, discontinue. Breastfeeding is <i>not</i> recommended while on statin tx.